Intrinsic Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Series A | ||
$7.2m | Series B | ||
$25.0m | Series C | ||
$21.0m | Series D | ||
$18.0m | Early VC | ||
N/A | $11.6m | Early VC | |
$17.3m | Early VC | ||
$17.9m | Early VC | ||
* | $28.0m | Early VC | |
$21.0m | Debt | ||
Total Funding | €133m |
Recent News about Intrinsic Therapeutics
EditIn-Thera is a pioneering company in the healthcare sector, specializing in innovative therapies for musculoskeletal disorders. The company primarily serves patients suffering from conditions such as herniated discs, offering advanced medical solutions to enhance patient outcomes. Operating in the medical technology market, In-Thera focuses on developing and providing cutting-edge treatments that address chronic pain and improve quality of life. The business model revolves around research and development, clinical trials, and partnerships with healthcare providers to bring their therapies to market. Revenue is generated through the sale of their proprietary medical devices and treatment solutions, as well as through collaborations with medical institutions.
Keywords: musculoskeletal, herniated discs, medical technology, chronic pain, patient outcomes, healthcare, advanced therapies, medical devices, clinical trials, innovation.